More recently, an increased level of NK, CD3+, CD4+, CD8+, and CD4+/CD8+ was registered in patients with primary liver cancer at 3 months after HIFU when compared with the baseline; moreover, the levels of IFN-γ and IL-2 significantly increased, while the levels of IL-4 and IL-10 decreased, reflecting a change in the Th1–Th2 ratio [137]. The gene discussed is CD8A; the disease is liver cancer.